232 related articles for article (PubMed ID: 33913072)
1. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.
Zhang MJ; Chen DS; Li S; Chen L; Qi YX; Zhang CJ
Invest New Drugs; 2021 Oct; 39(5):1436-1438. PubMed ID: 33913072
[TBL] [Abstract][Full Text] [Related]
2. Impact of
Magahis PT; Maron SB; Cowzer D; King S; Schattner M; Janjigian Y; Faleck D; Laszkowska M
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899129
[TBL] [Abstract][Full Text] [Related]
3. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
4. Impact of
Yu B; Peppelenbosch M; Fuhler G
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242721
[No Abstract] [Full Text] [Related]
5. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Che H; Xiong Q; Ma J; Chen S; Wu H; Xu H; Hou B
BMC Cancer; 2022 Aug; 22(1):904. PubMed ID: 35986342
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Apr; 21(16):4954-60. PubMed ID: 25945009
[TBL] [Abstract][Full Text] [Related]
7. Impact of
Noori M; Fayyaz F; Rezaei N
Immunotherapy; 2023 Jun; 15(9):657-667. PubMed ID: 37140002
[TBL] [Abstract][Full Text] [Related]
8.
Liu LP; Sheng XP; Shuai TK; Zhao YX; Li B; Li YM
World J Gastroenterol; 2018 Oct; 24(40):4565-4577. PubMed ID: 30386106
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics.
Yoon H; Kim N; Lee HS; Shin CM; Park YS; Lee DH; Jung HC; Song IS
Helicobacter; 2011 Oct; 16(5):382-8. PubMed ID: 21923684
[TBL] [Abstract][Full Text] [Related]
10.
Tonneau M; Nolin-Lapalme A; Kazandjian S; Auclin E; Panasci J; Benlaifaoui M; Ponce M; Al-Saleh A; Belkaid W; Naimi S; Mihalcioiu C; Watson I; Bouin M; Miller W; Hudson M; Wong MK; Pezo RC; Turcotte S; Bélanger K; Jamal R; Oster P; Velin D; Richard C; Messaoudene M; Elkrief A; Routy B
Oncoimmunology; 2022; 11(1):2096535. PubMed ID: 35832043
[TBL] [Abstract][Full Text] [Related]
11. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
Shi Y; Zheng H; Wang M; Ding S
Helicobacter; 2022 Apr; 27(2):e12878. PubMed ID: 35112435
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer.
Lv X; Zhao Y; Zhang L; Zhou S; Zhang B; Zhang Q; Jiang L; Li X; Wu H; Zhao L; Wei M; He M
J Cell Biochem; 2020 Feb; 121(2):1842-1854. PubMed ID: 31633246
[TBL] [Abstract][Full Text] [Related]
13. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.
Formica V; Morelli C; Patrikidou A; Murias C; Butt S; Nardecchia A; Lucchetti J; Renzi N; Shiu KK; Roselli M; Arkenau HT
Target Oncol; 2020 Jun; 15(3):327-336. PubMed ID: 32449030
[TBL] [Abstract][Full Text] [Related]
14. Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer.
Kim YI; Cho SJ; Lee JY; Kim CG; Kook MC; Ryu KW; Kim YW; Choi IJ
Cancer Res Treat; 2016 Jul; 48(3):1020-9. PubMed ID: 26582396
[TBL] [Abstract][Full Text] [Related]
15. Comparison between Resectable Helicobacter pylori-Negative and -Positive Gastric Cancers.
Kim HJ; Kim N; Yoon H; Choi YJ; Lee JY; Kwon YH; Yoon K; Jo HJ; Shin CM; Park YS; Park DJ; Kim HH; Lee HS; Lee DH
Gut Liver; 2016 Mar; 10(2):212-9. PubMed ID: 26087794
[TBL] [Abstract][Full Text] [Related]
16. Activation of CD3
Xue LJ; Mao XB; Liu XB; Gao H; Chen YN; Dai TT; Shao SW; Chen HM; Chu XY
Cancer Biol Ther; 2019; 20(6):866-876. PubMed ID: 30786815
[TBL] [Abstract][Full Text] [Related]
17. Screening and eradication of
Liou JM; Malfertheiner P; Lee YC; Sheu BS; Sugano K; Cheng HC; Yeoh KG; Hsu PI; Goh KL; Mahachai V; Gotoda T; Chang WL; Chen MJ; Chiang TH; Chen CC; Wu CY; Leow AH; Wu JY; Wu DC; Hong TC; Lu H; Yamaoka Y; Megraud F; Chan FKL; Sung JJ; Lin JT; Graham DY; Wu MS; El-Omar EM;
Gut; 2020 Dec; 69(12):2093-2112. PubMed ID: 33004546
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of microRNA-204 by Helicobacter pylori augments the NF-κB signaling pathway in gastric cancer development and progression.
Chen P; Guo H; Wu X; Li J; Duan X; Ba Q; Wang H
Carcinogenesis; 2020 Jun; 41(4):430-441. PubMed ID: 31873718
[TBL] [Abstract][Full Text] [Related]
19. [Helicobacter pylori and the progression of gastric cancer: a 10-year cohort study].
Ma JL; Zhang L; Pan KF; Liu WD; Feng GS; You WC
Zhonghua Yi Xue Za Zhi; 2005 Oct; 85(39):2758-61. PubMed ID: 16324316
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.
Nishizuka SS; Tamura G; Nakatochi M; Fukushima N; Ohmori Y; Sumida C; Iwaya T; Takahashi T; Koeda K;
J Surg Oncol; 2018 Apr; 117(5):947-956. PubMed ID: 29355977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
